Meanwhile, in gliomas and hemangiomas, MEG3 could inactivate PI3K/Akt pathway by sponging miR-93 and miR-494, respectively [84,85]; in pancreatic neuroendocrine tumors, MEG3 downregulates brain protein I3 (BRI3) expression by sponging miR-183, leading to the inactivation of p38/ERK/Akt and Wnt/β-catenin signaling pathways [64]. This evidence concerns the gene MEG3 and central nervous system cancer.